Sign up Australia
Proactive Investors - Run By Investors For Investors

Uranium Equities tops the ASX % Gainers as lithium anomaly identified

Uranium Equities has traded 39 million shares worth $480,000 in the first hour.
Uranium Equities tops the ASX % Gainers as lithium anomaly identified
The best performing stocks in morning trade

Uranium Equities Ltd (ASX:UEQ) is the top performer on the ASX this morning, with its shares more than doubling in value to $0.013, following a lithium anomaly being identified at Dundas in Western Australia.

UEQ has held the Dundas Project since June 2017, having pegged the area originally for gold prospectivity given its proximity to the nearby high-grade Viking Gold Project owned by Genesis Minerals Ltd (ASX:GMD).

The company’s tenement area sits on the edge of the Albany-Fraser Orogen which incorporates parts of the Archaean Yilgarn Craton, including the Norseman-Wiluna Greenstone Belt.

This province is known for hosting the world-class Tropicana gold deposit and the Nova-Bollinger nickel-copper deposit.

Company Name Code Last Change Volume
Uranium Equities UEQ $0.013 116.67% 38,512,874
Lakes Oil NL LKO $0.002 100% 16,628,774
Metals Australia Ltd MLS $0.005 25% 868,654
Genetic Technologies Ltd GTG $0.010 25% 4,095,971
Rision Ltd RNL $0.010 25% 564,332
Metalstech Ltd MTC $0.205 24.24% 3,755,200
Paradigm Biopharmaceuticals Ltd PAR $0.420 20% 556,008
Datadot Technology Ltd DDT $0.006 20% 854,052
Classic Minerals Ltd CLZ $0.006 20% 1,221,166
Kalamazoo Resources Ltd KZR $0.180 20% 577,665


View full . profile View Profile

Proactive Investors Australia Timeline

Related Articles

Mobile users holding phones up
September 05 2018
The mobile advertiser is placing itself at the forefront of the digital revolution as companies and brands increasingly look to the web as the next forefront of advertising
Media junkie
February 14 2018
In modern parlance, Ebiquity is making a pivot towards becoming the "world's leading tech-enabled marketing and media analytics consultancy"
April 16 2018
Global pharmaceutical R&D is forecast to reach $182bn by 2022 having grown at near 4% annually since 2006

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use